{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.71","upperLimit":"5.22","value":"4.27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"}],"units":"Participants"}],"description":"PFS was defined as the time from initiation of study drug until the date of PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg AIBW administered IV on Day 1 of every 3-week cycle (Q3W).","id":"OG000","title":"Mirvetuximab Soravtansine"}],"paramType":"MEDIAN","populationDescription":"INV Efficacy Evaluable population was defined as all participants who received at least 1 dose of study drug and who had measurable disease at baseline by investigator assessment per RECIST 1.1.","reportingStatus":"POSTED","timeFrame":"Up to approximately 15 months","title":"Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1","type":"SECONDARY","unitOfMeasure":"months"}